These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6769177)

  • 21. Binding of factor VIII to platelets in the presence of ristocetin.
    Zucker MB; Kim SJ; McPherson J; Grant RA
    Br J Haematol; 1977 Apr; 35(4):535-49. PubMed ID: 301398
    [No Abstract]   [Full Text] [Related]  

  • 22. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers.
    Weiss HJ; Meyer D; Rabinowitz R; Pietu G; Girma JP; Vicic WJ; Rogers J
    N Engl J Med; 1982 Feb; 306(6):326-33. PubMed ID: 6798442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor.
    Coller BS; Peerschke EI; Scudder LE; Sullivan CA
    Blood; 1983 Jan; 61(1):99-110. PubMed ID: 6336654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of vancomycin on ristocetin and bovine PAF-induced agglutination of human platelets.
    Baugh RF; Jacoby C; Brown JE; Hougie C
    Thromb Res; 1978 Mar; 12(3):511-21. PubMed ID: 306689
    [No Abstract]   [Full Text] [Related]  

  • 25. Platelet factor 4 does not promote von Willebrand factor binding to human platelets.
    Levine SP; Moake JL
    Thromb Res; 1984 Nov; 36(3):233-43. PubMed ID: 6440307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The binding of purified factor VIII/von Willebrand factor to collagens of differing type and form.
    Scott DM; Griffin B; Pepper DS; Barnes MJ
    Thromb Res; 1981 Dec 1-15; 24(5-6):467-72. PubMed ID: 6806932
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibitory effect of ristocetin and factor VIII/von Willebrand factor protein on human platelet adenylate cyclase activity.
    Kao KJ; Tsai BS; McKee PA; Lefkowitz RJ; Pizzo SV
    Thromb Res; 1983 May; 30(3):301-8. PubMed ID: 6408756
    [No Abstract]   [Full Text] [Related]  

  • 28. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma aggregating factor (bovine) for human platelets: a marker for study of antihemophilic and von Willebrand Factors.
    Griggs TR; Cooper HA; Webster WP; Wagner RH; Brinkhous KM
    Proc Natl Acad Sci U S A; 1973 Oct; 70(10):2814-8. PubMed ID: 4542779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Von Willebrand's disease.
    Hoyer LW
    Prog Hemost Thromb; 1976; 3():231-87. PubMed ID: 781732
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility.
    Coller BS
    J Clin Invest; 1978 May; 61(5):1168-75. PubMed ID: 307006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin.
    Sixma JJ; Schiphorst ME; Verweij CL; Pannekoek H
    Eur J Biochem; 1991 Mar; 196(2):369-75. PubMed ID: 1901037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenosine diphosphate induces binding of von Willebrand factor to human platelets.
    Fujimoto T; Hawiger J
    Nature; 1982 May; 297(5862):154-6. PubMed ID: 6281653
    [No Abstract]   [Full Text] [Related]  

  • 34. Interaction of platelets, von Willebrand factor, and ristocetin during platelet agglutination.
    Moake JL; Olson JD; Troll JH; Weinger RS; Peterson DM; Cimo PL
    J Lab Clin Med; 1980 Jul; 96(1):168-84. PubMed ID: 6967100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on the mechanism of ristocetin-induced platelet aggregation: binding of factor VIII to platelets.
    Schneider-Trip MD; Jenkins CS; Kahlé LH; Sturk A; ten Cate JW
    Br J Haematol; 1979 Sep; 43(1):99-112. PubMed ID: 508625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of calcium-dependent binding of endogenous factor VIII/von Willebrand factor to surface activated platelets.
    Furby FH; Berndt MC; Castaldi PA; Koutts J
    Thromb Res; 1984 Sep; 35(5):501-11. PubMed ID: 6435280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.
    Ruggeri ZM; Pareti FI; Mannucci PM; Ciavarella N; Zimmerman TS
    N Engl J Med; 1980 May; 302(19):1047-51. PubMed ID: 6767976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of platelet shape and membrane receptor binding by Ca2+-calmodulin complex.
    Kao KJ; Sommer JR; Pizzo SV
    Nature; 1981 Jul; 292(5818):82-4. PubMed ID: 6268985
    [No Abstract]   [Full Text] [Related]  

  • 39. Binding of porcine von Willebrand factor to human platelets in the presence of ristocetin.
    Silber P; Finlay TH
    Thromb Res; 1982 Jun; 26(5):351-8. PubMed ID: 7164028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor.
    Mohri H; Noguchi T; Kodama F; Itoh A; Ohkubo T
    Am J Clin Pathol; 1987 May; 87(5):663-8. PubMed ID: 3107370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.